The Journal of clinical psychiatry
-
Comparative Study Clinical Trial Controlled Clinical Trial
Treatment of major affective disorder with fluvoxamine.
A placebo-controlled, double-blind study of 63 inpatients with major affective disorder was performed to compare the safety and efficacy of fluvoxamine and imipramine. Results indicate that fluvoxamine and imipramine are superior to placebo and demonstrate a trend toward superiority of fluvoxamine over imipramine. Fluvoxamine was generally well tolerated in most patients.
-
Comparative Study Clinical Trial Controlled Clinical Trial
Implications of restrictive diagnosis for compliance to antidepressant drug therapy: alprazolam versus imipramine.
Early dropouts from a double-blind comparison of the therapeutic efficacy of alprazolam and imipramine were examined. The dropout rate across the total sample of 99 analyzable outpatients with major depression was 3 times higher in the imipramine treatment group. ⋯ Early termination in the imipramine group was concentrated in the group of depressed outpatients who failed to satisfy the Feighner criteria. Implications of these and other recently reported results for choice of drug treatment for depressed psychiatric outpatients are discussed.